Unknown

Dataset Information

0

Critical Role of B Cells in Toll-Like Receptor 7-Mediated Protection against Listeria monocytogenes Infection.


ABSTRACT: Toll-like receptors (TLR) trigger the immune system to mount a rapid innate response capable of protecting the host from a wide variety of bacterial and viral pathogens. There is interest in harnessing TLR agonists to reduce the susceptibility of at-risk populations to infection. However, the widespread prophylactic use of TLR agonists has been compromised by the need to administer them by parenteral injection. An exception is the TLR7/8 agonist R848, which can boost gastrointestinal and systemic immunity when administered orally. This work examines the effect of R848 on host susceptibility to Listeria monocytogenes in a murine challenge model and describes the underlying mechanisms. Results show that prophylactic administration of R848 significantly reduces susceptibility to infection of BALB/c mice, an effect that lasts 1 week. Oral R848 directly stimulated B cells to produce cytokines and Ig. In the absence of B cells, R848-mediated protection was lost. These findings support the use of oral R848 to reduce the susceptibility of at-risk individuals to infection and identify the critical role of B cells in TLR7-mediated resistance to bacterial infection.

SUBMITTER: Kayraklioglu N 

PROVIDER: S-EPMC6867860 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Critical Role of B Cells in Toll-Like Receptor 7-Mediated Protection against Listeria monocytogenes Infection.

Kayraklioglu Neslihan N   Horuluoglu Begum B   Elango Madhivanan M   Klinman Dennis M DM  

Infection and immunity 20191118 12


Toll-like receptors (TLR) trigger the immune system to mount a rapid innate response capable of protecting the host from a wide variety of bacterial and viral pathogens. There is interest in harnessing TLR agonists to reduce the susceptibility of at-risk populations to infection. However, the widespread prophylactic use of TLR agonists has been compromised by the need to administer them by parenteral injection. An exception is the TLR7/8 agonist R848, which can boost gastrointestinal and systemi  ...[more]

Similar Datasets

| S-EPMC375211 | biostudies-other
| S-EPMC3517125 | biostudies-literature
| S-EPMC3497413 | biostudies-literature
| S-EPMC4122265 | biostudies-literature
| S-EPMC2775488 | biostudies-literature
| S-EPMC5563510 | biostudies-literature
| S-EPMC4396484 | biostudies-literature
| S-EPMC4295506 | biostudies-literature
| S-EPMC9066004 | biostudies-literature
| S-EPMC3361567 | biostudies-literature